Network pharmacology is a newer tool for discovering drug targets and identifying newer lead molecules to treat diseases with complex pathology.1 Idiopathic pulmonary fibrosis (IPF) is one such disease where currently there is no remedy and only two specific drugs available for the treatment, nintedanib, and pirfenidone.2 Nintedanib is a specific antifibrotic agent that inhibits transforming growth factor beta (TGF-β) and thereby prevents the progression of IPF. This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.